![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Ent. | LSE:HCEG | London | Ordinary Share | GB00B6030H73 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHCEG RNS Number : 7916J Healthcare Enterprise Group PLC 07 April 2010 07 April 2010 Healthcare Enterprise Group PLC (AIM: HCEG) ("Healthcare Enterprise" or the "Group") Fertiligent medical device receives FDA approval Healthcare Enterprise, an international healthcare group, is pleased to announce that Reproductive Sciences Limited ("RSL" or "the Company"), in which it holds a 27% interest, has reported that its Fertiligent artificial insemination device has received formal approval from the US Food and Drugs Administration ("FDA") for its sale in the United States. Highlights: · FDA approval received · European CE approval for the final model received in March 2010 · Manufacturing & assembly agreement signed with Catheter Research, Inc of Indianapolis, Indiana, USA · Discussions underway to appoint US and international distributors with the aim of commencing sales later in 2010 RSL holds the worldwide sales and marketing rights to Fertiligent's products, including the "Evie" device. HCEG has contributed management oversight to RSL, with direct private investment from funders including Nigel Wray. RSL has focussed on Fertiligent's "Evie" product, a high quality, low cost intrauterine sperm pump to help assist infertile couples conceive. From initial trials conducted in Germany and Israel, Fertiligent offers infertile couples an enhanced intrauterine insemination success rate and the chance of avoiding invasive and costly artificial reproductive techniques such as in vitro fertilisation. The Company, RSL, owns 45% of the issued capital in the Israeli Fertiligent Limited company, with options to increase that holding to 78% of the fully diluted capital. RSL also owns the exclusive, worldwide sales & marketing rights to the Israeli Fertiligent company's products. Lyndon Gaborit, Executive Deputy Chairman of Healthcare Enterprise, commented: "We are delighted that this critical milestone has been achieved for the Fertiligent 'Evie' medical device. FDA approval, and the recently received CE approval for the final production version, significantly reduces risk and paves the way for a roll out of this exciting product around the world. Women's reproductive health is a significant and increasing market and this new product, which provides couples with a low cost alternative to existing reproduction methods such as IVF, should, we believe, find good market acceptance with associated returns to RSL's investors, including HCEG." For further information, please contact: +-----------------------------------+-------------------------+-----+ | Healthcare Enterprise Group PLC | | | | Lyndon Gaborit | Tel: +44 (0)20 7680 | | | | 3649 | | +-----------------------------------+-------------------------+-----+ | Daniel Stewart & Company plc | Tel + 44 (0)20 7776 6550 | | Andrew Edwards/Emma Earl | | | | | +-----------------------------------+-------------------------------+ | Bishopsgate Communications | | | | Robyn Samuelson / Giang Nguyen | Tel: +44 (0)20 7562 | | | | 3355 | | | | | | +-----------------------------------+-------------------------+-----+ Note to Editors Healthcare Enterprise Healthcare Enterprise Group PLC (HCEG) is a healthcare investment group which invests in synergistic products and services within the healthcare industry. It currently has two main investments: · Ebiox Limited - Patented decontamination and disinfectant products that are safe and alcohol free but substantially more effective than conventional methods at destroying embedded microorganisms. The Ebiox range includes hand hygiene products, surface disinfectants and products to clean and decontaminate surgical instruments. HCEG owns 20% of Ebiox Limited. · Reproductive Sciences Limited - Innovative slow release pump for intrauterine insemination, proven to significantly enhance pregnancy success rates. HCEG owns 27% of the Company. This information is provided by RNS The company news service from the London Stock Exchange END MSCUGUUWCUPUGBQ
1 Year Healthcare Enterprise Chart |
1 Month Healthcare Enterprise Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions